Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Smart” Software Emerging As Key To Artificial Pancreas For Diabetes Care

This article was originally published in The Gray Sheet

Executive Summary

The success of diabetes management technology leading to development of a closed-loop artificial pancreas will hinge on the incorporation of "intelligent" software than can adapt to individual patient needs, stakeholders say

You may also be interested in...



Medtronic Looks At Implantable Pancreas In Europe, Mulls U.S. Plans

Despite small glimpses of success with a fully implantable system to monitor glucose in a diabetic's bloodstream and automatically regulate insulin therapy, Medtronic is still mulling whether this approach will ultimately be the focus of its diabetes management program

Medtronic Looks At Implantable Pancreas In Europe, Mulls U.S. Plans

Despite small glimpses of success with a fully implantable system to monitor glucose in a diabetic's bloodstream and automatically regulate insulin therapy, Medtronic is still mulling whether this approach will ultimately be the focus of its diabetes management program

C-Path Institute Exec Targets “Points Of Pain” In Device Development

The Critical Path Institute's new Director of Medical Devices and Imaging, Ellen Feigal, MD, is working with device firms to identify key roadblocks to product development and clear the way to regulatory approval for those products

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel